AGGF1

Across TCGA pan-cancer cohorts, AGGF1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of AGGF1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where AGGF1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AGGF1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, HNSC, and BLCA are the cancer types where AGGF1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGGF1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.949	<.001	9	view →
HNSC	Female	III,IV	+0.747	.008	8	view →
BLCA	All	III,IV	+0.575	.002	7	view →
BRCA	All	III,IV	+0.528	<.001	6	view →
THCA	All	All	−0.246	.006	6	view →
CHOL	All	All	+1.348	<.001	5	view →
KICH	All	All	−0.791	<.001	5	view →
LUAD	All	All	+0.314	<.001	5	view →
STAD	All	II,III,IV	+0.454	.011	4	view →
KIRC	All	All	+0.214	.004	4	view →
COAD	Male	All	+0.315	.003	2	view →
ESCA	All	All	+0.377	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

AGGF1–LIHC

Open the LIHC breakdown →